IceCure Medical Ltd. submits Form 6-K for SEC approval of XSense™ Cryoablation System in Israel. Key insights into innovation and growth opportunities.
Discover key details from IceCure Medical Ltd.'s latest report on ordinary shares offering with Maxim Group LLC. Learn about terms, commissions, and legal context.
IceCure Medical Ltd. announces a 42% increase in ProSense® sales for 2024 in North America. Discover key insights from their January 2025 Form 6-K report and investor implications.
IceCure Medical Ltd. announces full compliance with Nasdaq rules in January 2025, enhancing investor trust and stock performance. Key insights from Form 6-K included.
Explore IceCure Medical Ltd.'s January 2025 report on its patent notice, regulatory filings, and market implications. Stay informed on advancements in medical technology.
Discover IceCure Medical Ltd.'s latest Form 6-K report detailing the appointment of Mr. Li Haixiang to the Board, shareholder control insights, and more. Stay informed on key corporate changes.